Kezar Life Sciences Inc (NASDAQ:KZR) insider Christopher J. Kirk bought 5,000 shares of Kezar Life Sciences stock in a transaction dated Tuesday, August 13th. The stock was purchased at an average price of $4.61 per share, for a total transaction of $23,050.00. The purchase was disclosed in a filing with the SEC, which is available through this link.

Shares of NASDAQ:KZR traded up $0.10 on Thursday, hitting $4.83. The stock had a trading volume of 106,700 shares, compared to its average volume of 95,201. Kezar Life Sciences Inc has a twelve month low of $4.12 and a twelve month high of $36.33. The company has a quick ratio of 20.32, a current ratio of 20.32 and a debt-to-equity ratio of 0.06. The company has a 50 day moving average of $6.15. The company has a market cap of $86.12 million, a P/E ratio of -2.14 and a beta of 0.61.

Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.02. On average, sell-side analysts forecast that Kezar Life Sciences Inc will post -1.98 EPS for the current fiscal year.

Several equities research analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Kezar Life Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, July 10th. Cowen restated a “buy” rating on shares of Kezar Life Sciences in a research note on Thursday, August 8th. ValuEngine upgraded shares of Kezar Life Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, HC Wainwright assumed coverage on shares of Kezar Life Sciences in a research note on Monday, July 29th. They issued a “buy” rating and a $15.00 target price on the stock. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $17.50.

Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in shares of Kezar Life Sciences by 32.9% in the second quarter. BlackRock Inc. now owns 844,391 shares of the company’s stock valued at $6,512,000 after buying an additional 208,816 shares during the last quarter. Victory Capital Management Inc. raised its holdings in Kezar Life Sciences by 105.7% during the 2nd quarter. Victory Capital Management Inc. now owns 461,453 shares of the company’s stock worth $3,558,000 after purchasing an additional 237,110 shares during the last quarter. Northern Trust Corp raised its holdings in Kezar Life Sciences by 4.6% during the 2nd quarter. Northern Trust Corp now owns 132,888 shares of the company’s stock worth $1,025,000 after purchasing an additional 5,882 shares during the last quarter. Morgan Stanley raised its holdings in Kezar Life Sciences by 923.4% during the 2nd quarter. Morgan Stanley now owns 74,982 shares of the company’s stock worth $578,000 after purchasing an additional 67,655 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Kezar Life Sciences by 126.7% during the 4th quarter. Geode Capital Management LLC now owns 58,046 shares of the company’s stock worth $1,369,000 after purchasing an additional 32,441 shares during the last quarter. 50.97% of the stock is owned by institutional investors and hedge funds.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.

Recommended Story: What are the FAANG Stocks?

Insider Buying and Selling by Quarter for Kezar Life Sciences (NASDAQ:KZR)

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.